Protagenic Therapeutics
New York, US
Protagenic is a neuropeptide medicine company developing treatments that modulate the brain's stress-control chemistry, based on Teneurin C-terminal Associated Peptides (TCAPs). It targets neuropsychiatric disorders driven by stress overdrive, aiming for rapid onset without the side effects of conventional approaches.
Founders & leadership
RZ
Robert ZiroyanNamed on SEC filing
HH
Hartoun HartounianNamed on SEC filing
GA
Garo ArmenNamed on SEC filing
KB
Khalil BarrageNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$375K disclosed across 1 round · 2010
▶$375KraisedFeb 2012 · 5 investors · BiotechnologyRule 506(b)
▶$375KraisedFeb 2012 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert ZiroyanExecutive Officer
- Hartoun HartounianDirector
- Garo ArmenDirector
- Khalil BarrageDirector
- Offering amount
- $375K
- Amount sold
- $375K
- First sale
- Sep 2010
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Protagenic Therapeutics do?
- Protagenic is a neuropeptide medicine company developing treatments that modulate the brain's stress-control chemistry, based on Teneurin C-terminal Associated Peptides (TCAPs). It targets neuropsychiatric disorders driven by stress overdrive, aiming for rapid onset without the side effects of conventional approaches.
- How much funding has Protagenic Therapeutics raised?
- Protagenic Therapeutics has disclosed $375K raised across 1 round.
- Where is Protagenic Therapeutics headquartered?
- Protagenic Therapeutics is headquartered in New York, US.